TCT 2023
Here are the most important scientific articles of the TCT 2023 Congress.
If you cannot view the articles, click here
TCT 2023 | COMPARE 60/80 HBR TRIAL
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, ...
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, ...
TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome
This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one ...
This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one ...
TCT 2023 | ISAR-DESIRE 3: 10-Year Results
In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents ...
In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents ...
TCT 2023 | COMPARE 60/80 HBR TRIAL
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, ...
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, ...
TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons
This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated ...
This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated ...
TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome
This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one ...
This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one ...
TCT 2023 | SWEDEHEART, Evolution at 5 Years
This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR. Population characteristics were similar, except ...
This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR. Population characteristics were similar, except ...
TCT 2023 | CLASP IID Study 1-Year Results: PASCAL vs. MITRACLIP for Degenerative Mitral Regurgitation
The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely recognized. However, only 15% of patients are referred for surgery due to their ...
The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely recognized. However, only 15% of patients are referred for surgery due to their ...
TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus
Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents a small aortic annulus (SAA), especially women. Treating this group of patients ...
Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents a small aortic annulus (SAA), especially women. Treating this group of patients ...
TCT 2023 | TRILUMINATE Trial: Health Status after TriClip
Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status. ...
Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status. ...
TCT 2023 | PARTNER 3 Low Risk: 5-Year Follwup
TCT has presented the 5-year clinical and echocardiographic outcomes of low-risk patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR) using ...
TCT has presented the 5-year clinical and echocardiographic outcomes of low-risk patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR) using ...
TCT 2023 | EXPAND G4
The EXPAND G4 is a prospective multicenter single arm study on real life patients. It included a total 1,164 patients with primary (PMR) and secondary (SMR) ...
The EXPAND G4 is a prospective multicenter single arm study on real life patients. It included a total 1,164 patients with primary (PMR) and secondary (SMR) ...
TCT 2023 | ALIGN AR Trial
Dr. Thourani has presented the ALIGN AR, a single arm, multicenter and non-blinded trial on the use of JenaValve in symptomatic patients with severe aortic regurgitation and high surgical ...
Dr. Thourani has presented the ALIGN AR, a single arm, multicenter and non-blinded trial on the use of JenaValve in symptomatic patients with severe aortic regurgitation and high surgical ...
TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up
In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical ...
In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement (TAVR) in younger patients, with an average age of 74 years, as observed in US medical ...
TCT 2023 | SWISS-APERO: One-Year Events After Left Atrial Appendage Closure with Amulet or Watchman FLX Device
It has been observed that the persistence of an opening in the left atrial appendage after percutaneous closure (LAAC) is associated with a higher risk of embolic events. Among the most commonly ...
It has been observed that the persistence of an opening in the left atrial appendage after percutaneous closure (LAAC) is associated with a higher risk of embolic events. Among the most commonly ...
TCT 2023 | The WATCH-TAVR Study
In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting ...
In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting ...
TCT 2023 The LIFE-BTK Trial
This was a randomized study including 261 patients treated with infrapatellar percutaneous transluminal angioplasty.173 of these patients received an everolimus bioresorbable scaffold while the ...
This was a randomized study including 261 patients treated with infrapatellar percutaneous transluminal angioplasty.173 of these patients received an everolimus bioresorbable scaffold while the ...